Skip to main content
. 2022 Mar 11;12:858797. doi: 10.3389/fonc.2022.858797

Table 2.

Association between the percentage of innate immunity cells and the clinicopathological characteristics of the analyzed cohort of GCT patients.

Total white blood cell population (CD45+ population) Total leukocyte subpopulations (percentage) Monocyte subpopulations (percentage)
Neutrophils percentage Monocytes percentage Classical monocytes percentage Intermediate monocytes percentage Non-classical monocytes percentage
Variable N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value
All patients
Histology
 Pure seminoma 22 60.7 2.9 62.0 0.63254 22 10.0 0.7 9.4 0.39843 15 87.6 1.8 86.5 0.55907 11 4.1 0.8 3.6 0.14329 15 5.7 0.9 5.0 0.42177
 Non-seminoma or mixed GCTs 62 63.2 1.7 62.1 62 9.3 0.4 9.3 53 86.5 1.0 87.4 33 5.4 0.4 5.2 51 4.9 0.5 4.6
IGCCCG risk group
 Good prognosis 49 59.7 1.7 61.1 0.00005 49 9.7 0.5 9.4 0.12092 35 87.1 1.2 86.5 0.20119 23 4.6 0.5 3.6 0.23378 33 5.1 0.6 4.6 0.09703
 Intermediate prognosis 6 67.6 4.8 69.0 6 11.9 1.3 14.0 6 85.4 3.0 86.7 3 5.5 1.5 5.9 6 6.9 1.4 4.9
 Poor prognosis 16 76.8 2.9 78.4 16 7.9 0.8 7.5 15 88.2 1.9 90.8 9 6.2 0.9 5.5 15 3.6 0.9 2.8
Number of metastatic sites
 0 to 2 67 59.7 1.5 59.8 0.00015 67 9.4 0.4 9.3 0.73838 53 85.7 0.9 86.4 0.01983 35 5.1 0.4 4.4 0.65199 52 5.5 0.5 5.1 0.00635
 ≥ 3 17 73.6 3.0 73.4 17 9.8 0.8 10.2 15 90.2 1.7 90.7 9 5.2 0.9 5.2 14 3.3 0.9 3.3
Retroperitoneal LN metastases
 Absent 22 58.4 2.8 57.7 0.04037 22 9.5 0.7 9.1 0.54158 19 86.0 1.6 84.8 0.24813 14 4.8 0.7 3.7 0.65014 19 5.1 0.8 5.0 0.58557
 Present 62 64.0 1.7 64.6 62 9.5 0.4 9.7 49 87.0 1.0 88.3 30 5.3 0.5 5.3 47 5.1 0.5 4.6
Mediastinal LN metastases
 Absent 71 60.1 1.5 60.4 0.00022 71 9.6 0.4 9.3 0.39003 57 85.9 0.9 86.4 0.00615 38 5.2 0.4 4.8 0.91828 55 5.5 0.4 5.0 0.00655
 Present 13 75.5 3.4 78.3 13 8.8 0.9 8.1 11 91.2 2.0 92.1 6 4.8 1.1 5.3 11 3.1 1.0 3.0
Lung metastases
 Absent 66 59.2 1.5 59.9 0.00004 66 9.7 0.4 9.3 0.40738 52 86.3 1.0 86.3 0.02503 34 5.1 0.4 4.8 0.91080 51 5.5 0.5 5.0 0.01346
 Present 18 74.8 2.8 74.8 18 9.0 0.8 8.8 16 88.2 1.8 91.0 10 5.1 0.8 5.2 15 3.7 0.9 3.0
Brain metastases
 Absent 82 62.1 1.5 61.8 0.05281 82 9.6 0.4 9.4 0.18672 66 86.5 0.8 86.7 0.02682 NA 64 5.2 0.4 4.8 0.03003
 Present 2 81.6 9.3 81.6 2 7.0 2.3 7.0 2 95.8 4.9 95.8 2 0.8 2.3 0.8
Non-pulmonary visceral metastases
 Absent 72 59.9 1.4 59.9 000001 72 9.6 0.4 9.4 0.32812 56 85.6 0.9 86.3 0.00097 38 5.1 0.4 4.8 0.51582 54 5.7 0.4 5.1 0.00005
 Present 12 78.4 3.4 79.4 12 8.8 0.9 7.6 12 91.9 1.9 92.5 6 5.5 1.1 5.3 12 2.3 0.9 2.1
S – stage
 0-2 70 59.6 1.4 59.9 0.00002 70 9.8 0.4 9.5 0.07567 55 86.6 1.0 86.5 0.14478 36 4.9 0.4 4.3 0.22353 53 5.1 0.5 4.9 0.14674
 3 14 77.1 3.2 79.4 14 8.1 0.8 7.4 13 87.2 2.0 90.8 8 6.0 0.9 5.7 13 4.1 0.9 3.7
Total white blood cell population (CD45+ population) Total leukocyte subpopulations (percentage) Lymphocyte subpopulations (percentage)
PMNs-MDSC percentage Eosinophils percentage Basophils percentage NKT cells percentage CD4+ NKT cells percentage
Variable N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value
All patients
Histology
 Pure seminoma 13 0.2 0.6 0.2 0.53233 22 3.1 0.6 1.9 0.63978 22 0.7 0.07 0.6 0.89476 22 2.6 0.6 1.6 0.44796 11 0.6 0.2 0.2 0.83252
 Non-seminoma or mixed GCTs 42 0.9 0.4 0.2 62 2.4 0.3 1.6 62 0.6 0.04 0.6 60 2.2 0.4 1.3 34 0.3 0.1 0.2
IGCCCG risk group
 Good prognosis 30 0.4 0.4 0.2 0.63051 49 3.0 0.4 2.0 0.01080 49 0.7 0.04 0.6 0,00880 48 2.1 0.4 1.3 0.93130 24 0.4 0.1 0.2 0.75830
 Intermediate prognosis 5 0.2 1.1 0.2 6 1.9 1.0 1.6 6 0.7 0.1 0.6 6 2.2 1.0 0.9 3 1.0 0.3 0.1
 Poor prognosis 11 2.3 0.7 0.2 16 1.2 0.6 0.8 16 0.4 0.07 0.3 15 1.8 0.6 1.8 9 0.3 0.2 0.2
Number of metastatic sites
 0 to 2 43 0.8 0.4 0.2 1.00000 67 2.9 0.3 1.9 0.06870 67 0.7 0.04 0.7 0.10400 66 2.3 0.3 1.3 0.88833 35 0.3 0.1 0.2 0.69195
 ≥ 3 12 0.2 0.7 0.2 17 1.5 0.6 1.0 17 0.5 0.08 0.5 16 2.2 0.7 1.6 10 0.5 0.2 0.2
Retroperitoneal LN metastases
 Absent 16 1.1 0.6 0.2 0.91141 22 2.3 0.6 1.6 0.62530 22 0.7 0.07 0.7 0.47314 22 3.0 0.6 1.4 0.31501 14 0.4 0.1 0.2 0.81567
 Present 39 0.5 0.4 0.2 62 2.7 0.3 1.9 62 0.6 0.04 0.6 60 2.0 0.3 1.3 31 0.4 0.1 0.2
Mediastinal LN metastases
 Absent 45 0.5 0.3 0.2 0.60784 71 2.8 0.3 1.8 0.07696 71 0.7 0.04 0.7 0.01845 70 2.4 0.3 1.4 0.36530 39 0.4 0.1 0.2 0.33247
 Present 10 1.7 0.7 0.2 13 1.5 0.7 1.1 13 0.5 0.09 0.4 12 1.5 0.8 1.3 6 0.3 0.2 0.1
Lung metastases
 Absent 43 0.7 0.4 0.2 0.34823 66 3.0 0.3 1.9 0.00642 66 0.7 0.04 0.6 0.09420 64 2.3 0.3 1.3 0.78802 34 0.3 0.1 0.2 0.65316
 Present 12 0.9 0.7 0.2 18 1.3 0.6 1.0 18 0.5 0.08 0.4 18 2.3 0.6 1.4 11 0.5 0.2 0.2
Brain metastases
 Absent 53 0.5 0.3 0.2 0.06188 82 2.6 0.3 1.7 0.03220 82 0.7 0.04 0.6 0.02295 80 2.3 0.3 1.4 0.04093 NA
 Present 2 7.7 1.3 7.7 2 0.2 1.8 0.2 2 0.2 0.2 0.2 2 0.1 1.9 0.1
Non-pulmonary visceral metastases
 Absent 47 0.3 0.3 0.2 0.07512 72 2.8 0.3 1.9 0.00194 72 0.7 0.04 0.7 0.00189 71 2.3 0.3 1.3 0.90253 39 0.4 0.1 0.2 0.59286
 Present 8 3.1 0.7 0.3 12 1.0 0.7 0.6 12 0.4 0.09 0.3 11 2.0 0.8 1.8 6 0.3 0.2 0.2
S – stage
 0-2 44 0.7 0.3 0.2 0.41155 70 2.9 0.3 1.9 0.00598 70 0.7 0.04 0.7 0.00704 68 2.3 0.3 1.3 0.71158 37 0.3 0.1 0.2 0.20665
 3 11 1.0 0.7 0.2 14 1.2 0.7 0.8 14 0.4 0.09 0.4 14 2.3 0.7 1.8 8 0.6 0.2 0.2
Total white blood cell population (CD45+ population) Lymphocyte subpopulations (percentage) Total leukocyte subpopulations (percentage) Subpopulation of DCs (percentage)
CD8+ NKT cells percentage NK cells percentage Dendritic cells (cDCs) percentage Plasmacytoid dendritic cells (pDCs) percentage DC2s+ percentage
Variable N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value N Mean SEM Median p-value
All patients
Histology
 Pure seminoma 11 2.6 0.6 1.9 0.53653 22 13.4 1.8 12.2 0.36522 15 1.0 0.1 0.8 0.32810 15 0.2 0.02 0.1 0.55871 14 21.8 2.4 20.3 0.93412
 Non-seminoma or mixed GCTs 35 2.0 0.3 1.3 62 12.1 1.1 10.3 52 0.8 0.06 0.7 50 0.1 0.01 0.1 49 21.1 1.3 21.4
IGCCCG risk group
 Good prognosis 25 2.2 0.4 1.1 0.62858 49 11.0 1.2 10.0 0.11766 37 0.9 0.08 0.8 0.00342 36 0.2 0.01 0.2 0.00076 34 23.3 1.4 23.2 0.00714
 Intermediate prognosis 3 2.2 1.2 0.5 6 24.2 3.4 22.5 5 1.1 0.2 1.2 5 0.1 0.03 0.09 5 15.3 3.7 13.0
 Poor prognosis 9 1.7 0.7 1.9 16 13.0 2.1 9.9 14 0.5 0.1 0.4 13 0.07 0.02 0.06 14 15.3 2.2 15.4
Number of metastatic sites
 0 to 2 36 2.2 0.3 1.2 0.98938 67 12.5 1.0 10.5 0.81946 53 0.9 0.06 0.8 0.01358 53 0.2 0.01 0.2 0.00825 51 23.3 1.1 23.1 0.00016
 ≥ 3 10 1.9 0.6 1.6 17 12.0 2.1 10.8 14 0.6 0.1 0.6 12 0.1 0.02 0.1 12 12.5 2.2 12.9
Retroperitoneal LN metastases
 Absent 14 2.5 0.5 1.4 0.58294 22 11.3 1.8 10.5 0.94323 19 0.8 0.1 0.8 0.49537 19 0.2 0.02 0.2 0.00825 18 24.3 2.0 25.3 0.07021
 Present 32 2.0 0.3 1.2 62 12.8 1.1 10.9 48 0.8 0.07 0.8 46 0.1 0.01 0.1 45 20.0 1.3 17.7
Mediastinal LN metastases
 Absent 40 2.2 0.3 1.3 0.61316 71 12.7 1.0 10.5 0.52417 57 0.9 0.06 0.8 0.00896 56 0.2 0.01 0.1 0.02360 54 22.2 1.2 21.8 0.03228
 Present 6 1.5 0.8 1.5 13 10.7 2.4 10.8 10 0.5 0.1 0.4 9 0.1 0.03 0.06 9 15.5 2.8 13.0
Lung metastases
 Absent 35 2.2 0.3 1.4 0.92818 66 11.7 1.0 10.1 0.23047 52 0.9 0.06 0.8 0.00112 52 0.2 0.01 0.2 0.00086 50 23.3 1.1 23.5 0.00014
 Present 11 1.9 0.6 1.3 18 15.1 2.0 12.1 15 0.5 0.1 0.5 13 0.1 0.02 0.07 13 13.2 2.2 12.8
Brain metastases
 Absent NA 82 12.6 0.9 10.9 0.13456 65 0.8 0.06 0.8 0.04267 63 0.1 0.01 0.1 0.03012 61 21.1 1.1 20.9 0.69503
 Present 2 5.4 6.0 5.4 2 0.3 0.3 0.3 2 0.03 0.05 0.03 2 24.9 6.2 24.9
Non-pulmonary visceral metastases
 Absent 40 2.2 0.3 1.2 0.81940 72 12.5 1.0 10.7 0.71086 56 0.9 0.06 0.8 0.00034 56 0.2 0.01 0.2 0.00029 53 22.3 1.2 22.1 0.03355
 Present 6 1.7 0.8 1.7 12 12.1 2.5 9.9 11 0.4 0.1 0.4 9 0.06 0.02 0.03 10 15.8 2.7 13.4
S – stage
 0-2 38 2.1 0.3 1.2 0.42546 70 11.8 1.0 10.3 0.33695 56 0.9 0.06 0.8 0.03222 55 0.2 0.01 0.2 0.00998 52 22.8 1.1 22.7 0.00196
 3 8 2.2 0.7 2.0 14 15.6 2.2 12.1 11 0.6 0.1 0.6 10 0.1 0.02 0.1 11 13.8 2.5 12.8

SEM, standard error of the mean. Values of p ≤ 0.05 are considered as significant. Significant p values are in bold. Variability of total number of examined patients samples (N) within the evaluated subpopulations were due to the individual technical limitations, including missing antibodies or bad quality of examined samples.